ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discuss the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).

Cost of Care

Colorectal Cancer

John L. Marshall, MD

John L. Marshall, MD, on Issues of Value in Colorectal Cancer Treatment

John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.

Prostate Cancer

Nicholas David James, MD, PhD, and Celestia S. Higano, MD

Nicholas David James, MD, PhD, and Celestia S. Higano, MD, on Results From the STAMPEDE Trial on Hormone-Naive Prostate Cancer

Celestia S. Higano, MD, of the University of Washington, and Nicholas David James, MD, PhD, of Warwick Medical School, discuss data showing improvements in survival from adding docetaxel in men starting long-term hormone therapy for the first time (Abstract 5001).

Multiple Myeloma

Saad Usmani, MD

Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma

For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD, of the Levine Cancer Institute, provides the highlights of this study on the first monoclonal antibody to show promise in multiple myeloma (Abstract LBA8512).

Issues in Oncology

James H. Doroshow, MD

James H. Doroshow, MD, on The NCI’s MATCH Trial

James H. Doroshow, MD, of the National Cancer Institute, describes a new precision medicine initiative called the MATCH trial: Molecular Analysis for Therapy Choice. In 2,400 NCI clinical trial sites, 3,000 patients will be screened and their tumors analyzed to determine whether they contain genetic abnormalities for which a targeted drug exists.

Sep

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

John L. Marshall, MD, on Issues of Value in Colorectal Cancer Treatment

Nicholas David James, MD, PhD, and Celestia S. Higano, MD, on Results From the STAMPEDE Trial on Hormone-Naive Prostate Cancer

Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma

James H. Doroshow, MD, on The NCI’s MATCH Trial

Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer

Prostate Cancer NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT

ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma

Hypofractionated Salvage Radiotherapy Evaluated After Prostatectomy for Biochemical Recurrence

Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer